Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy and association with lymph node metastasis of the systemic immune-inflammation index in thyroid cancer: a systematic review and meta-analysis.

Frontiers in immunology·2026
Same author

Comparative Evaluation of the Antidiabetic, Hypolipidemic and Antioxidant Effects of <i>Polygonum persicaria</i> L. Herb and <i>Vaccinium myrtillus</i> L. Leaves in Streptozotocin-Induced Diabetes.

Molecules (Basel, Switzerland)·2026
Same author

A Rare Case of Extensive Relapsing Disseminated Hydatid Disease with Multi-Organ Involvement: A Case Report.

Diseases (Basel, Switzerland)·2026
Same author

From Species Identification to Empirical Therapy: A Machine Learning and Rule-Based Decision Support Framework for Antifungal Resistance Prediction in ICU <i>Candida</i> Infections.

Medical sciences (Basel, Switzerland)·2026
Same author

Host, Pathogen, and Pulmonary Anatomy in Pneumonia: An Integrated Imaging and Clinical Perspective.

Diagnostics (Basel, Switzerland)·2026
Same author

Shifting Epidemiology and Antifungal Susceptibility Patterns of Clinical Fungal Isolates in an Intensive Care Unit (ICU) from Bucharest, Romania: A Retrospective Observational Study.

Antibiotics (Basel, Switzerland)·2026

Related Experiment Video

Updated: May 5, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Non-Small-Cell Lung Cancer: From Histopathological Classification to Precision Oncology-A Narrative Review.

Simona-Maria Roșu1, Viorel Biciușcă2, Sorina-Ionelia Stan2

  • 1Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Journal of Clinical Medicine
|May 4, 2026
PubMed
Summary
This summary is machine-generated.

Precision oncology redefines Non-Small-Cell Lung Cancer (NSCLC) treatment. Comprehensive molecular testing and integrated data are crucial for tailoring therapies and improving patient outcomes in this prevalent cancer.

Keywords:
actionable oncogenic drivershistological subtypesmultidisciplinary managementnon-small-cell lung cancertreatment

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

559
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.1K

Related Experiment Videos

Last Updated: May 5, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

559
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.1K

Area of Science:

  • Oncology
  • Genetics
  • Pathophysiology

Background:

  • Non-Small-Cell Lung Cancer (NSCLC) is a leading cause of cancer mortality globally.
  • Traditional histopathological classification is insufficient for modern precision oncology.
  • Evolving understanding necessitates integrated diagnostic and therapeutic approaches.

Purpose of the Study:

  • To provide a comprehensive review of NSCLC evaluation, integrating pathophysiology, histology, and molecular analyses.
  • To highlight actionable genetic alterations and their role in targeted therapy selection.
  • To discuss the impact of immune checkpoint inhibitors and emerging biomarkers for personalized treatment.

Main Methods:

  • Review of current literature on NSCLC diagnosis and treatment.
  • Integration of pathophysiological mechanisms, histological, immunohistochemical, and molecular data.
  • Analysis of actionable genetic alterations (EGFR, ALK, ROS1, BRAF, KRAS) and immune biomarkers.

Main Results:

  • Histology alone is inadequate; molecular profiling is essential for treatment decisions.
  • Targeted therapies based on specific genetic alterations (e.g., EGFR, ALK) demonstrate significant efficacy.
  • Immune checkpoint inhibitors offer benefits for selected NSCLC patients.
  • Emerging biomarkers and combination strategies are advancing patient stratification.

Conclusions:

  • Comprehensive molecular testing and integrated data analysis are critical for individualized NSCLC management.
  • Precision oncology requires a multidisciplinary approach combining tumor biology with diagnostic and therapeutic strategies.
  • Future directions involve refining patient stratification and improving outcomes through novel biomarkers and combination therapies.